中文 Chinese
英文 English
Site Map
About Us
Company
Board
Management
Partnerships
Activities
Pipeline
Ibalizumab (TMB-355) Intravenous Infusion
Ibalizumab (TMB-355) Intravenous Push
Ibalizumab (TMB-355) Intramuscular Injection
TMB-365
TMB-365/TMB-380 (TMB-365 and TMB-380 combination)
CDMO Service
Overview
Our advantage
Contract Development & Manufacturing Service
Our services
News
Recent News
Announcement
Events
Biotech Column
Investor Relations
Company
Company Profile
Company Presentation
Corporate Governance
Organization
Board
Committee
Internal Audit
Major Internal Policies
Financials
Monthly Revenue
Financial Reports
Shareholders' Services
Major Shareholders
Dividend Information
Investor and Stock Information
Shareholder's Meeting
Contact Us
中文 Chinese
英文 English
Site Map
Home
News
Announcement
Announcement
Select year:
All
2016
2015
2016-10-30
Ibalizumab study 301 presenation at IDWeek 2016
2015-11-23
TaiMed Biologics IPO
2015-11-23
Presentation for IPO
«
1
»
